Our mission is to deliver first-in-class medicines to address the critical need for cost-effective, disease-modifying treatments for neurodegeneration that can reach broad patient populations.
Our Science and Therapeutic Focus
We are developing a pipeline of potent small molecule heterobifunctional TRIMTAC® and TRIMGLUE® degraders that harness the innate properties of TRIM21, a novel E3 ligase that is expressed in most tissues.
Our therapeutics potently and selectively degrade disease-causing protein aggregates, while preserving healthy native versions of these proteins to maintain proper cell function.
Our portfolio of programs is focused on Alzheimer’s, Parkinson’s, Huntington’s and other neurodegenerative and inflammatory disorders.
Leadership
TRIMTECH is led by a highly experienced team with vast expertise in targeted protein degradation (TPD) and a proven track record of developing innovative technologies and novel therapeutics.
World-renowned Scientific Foundations
The company is built on 20 years of pioneering research into the biology of TRIM21, led by its academic co-founders, Dr. Leo James, Group Leader at the MRC Laboratory of Molecular Biology, and Dr. William McEwan, Group Leader at the UK Dementia Research Institute, University of Cambridge.
Leading Investor Syndicate
A private company, TRIMTECH Therapeutics raised $31 million (£25 million) in a seed financing round in March 2025.
Location
The Company is located in Cambridge UK, one of the most influential and innovative biotech and academic hubs in the world.
© TRIMTECH Therapeutics
TRIMTAC, TRIMVEC and TRIMGLUE are registered trademarks of TRIMTECH Therapeutics Ltd.
